Publications by authors named "Collin M Blakely"

26Publications

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Cell 2020 Sep 20;182(5):1232-1251.e22. Epub 2020 Aug 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484178PMC
September 2020

Impact of concurrent genomic alterations in epidermal growth factor receptor ()-mutated lung cancer.

J Thorac Dis 2020 May;12(5):2883-2895

Department of Medicine, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2020.03.78DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330397PMC
May 2020

Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.

Clin Cancer Res 2020 Jul 4;26(14):3499-3500. Epub 2020 May 4.

Division of Hematology and Oncology, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-1129DOI Listing
July 2020

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.

Expert Rev Anticancer Ther 2019 12 6;19(12):1061-1075. Epub 2019 Dec 6.

Department of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1699792DOI Listing
December 2019

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.

Authors:
Collin M Blakely

Clin Cancer Res 2019 12 14;25(24):7269-7271. Epub 2019 Oct 14.

Department of Medicine, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-2861DOI Listing
December 2019

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.

Curr Oncol Rep 2019 02 26;21(3):21. Epub 2019 Feb 26.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0770-xDOI Listing
February 2019

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Clin Lung Cancer 2019 03 20;20(2):e137-e141. Epub 2018 Nov 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.003DOI Listing
March 2019

Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 01 31;19(1):58-64. Epub 2017 May 31.

Division of Adult Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304173015
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2017.05.015DOI Listing
January 2018

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

Clin Lung Cancer 2016 09 8;17(5):466-469. Epub 2016 Jun 8.

Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378381PMC
September 2016

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Cell Rep 2015 Apr 2;11(1):98-110. Epub 2015 Apr 2.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394036PMC
April 2015

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.

Cancer Discov 2012 Oct;2(10):872-5

Department of Medicine, Division of Hematology and Oncology, University of California at San Francisco San Francisco, California 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475614PMC
October 2012

Developmental stage determines the effects of MYC in the mammary epithelium.

Development 2005 Mar 2;132(5):1147-60. Epub 2005 Feb 2.

Departments of Cancer Biology, Cell and Developmental Biology, Medicine, and The Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6160, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dev.01655DOI Listing
March 2005

P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress.

Biochemistry 2002 Oct;41(39):11878-87

Department of Microbiology, The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi020397eDOI Listing
October 2002

The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation.

J Biol Chem 2002 Sep 22;277(39):36109-17. Epub 2002 Jul 22.

Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, 98195, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M205109200
Publisher Site
http://dx.doi.org/10.1074/jbc.M205109200DOI Listing
September 2002